Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.